Eight Capital analyst Graeme Kreindler maintained a Sell rating on Canopy Growth (CGC – Research Report) today and set a price target of C$5.50. The company’s shares closed last Friday at $5.52, close to its 52-week low of $4.82.
According to TipRanks.com, Kreindler is ranked #6472 out of 7885 analysts.
Canopy Growth has an analyst consensus of Strong Sell, with a price target consensus of $5.64.
See the top stocks recommended by analysts >>
The company has a one-year high of $26.96 and a one-year low of $4.82. Currently, Canopy Growth has an average volume of 7.13M.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Read More on CGC:
- Analysts Offer Insights on Industrial Goods Companies: TC Energy (TRP), Pembina Pipeline (PBA) and Enbridge (ENB)
- Vaxart Has Great News if You’re Afraid of Covid-19 — And You’re a Hamster
- Celsius Holdings Has Potential, but May Get Cheaper
- Covenant Logistics Group (CVLG) Receives a Rating Update from a Top Analyst
- Yes, Nvidia Stock is Expensive — But Oppenheimer Says It’s Worth the Price
